Biotia and New York City-based Hospital for Special Surgery are partnering for diagnostics for detecting prosthetic joint infection, according to a Sept. 2 news release.
Biotia uses next-generation sequencing and artificial intelligence to microorganisms and antimicrobial resistance. HSS will leverage the company’s tools under the collaboration.
“Through this collaboration, we’re uniting a cross-disciplinary team across academia and industry to look at a complex clinical challenge from multiple angles,” Vijay Nair, managing director of innovation at HSS, said in the release. “By combining our deep clinical expertise with Biotia’s diagnostic platform, our hope is to address a pressing need in the diagnosis and management of prosthetic joint infection so patients can get back to doing what they love following joint replacement surgery.”
